dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Griffin, CL | |
dc.contributor.author | Silva, P | |
dc.contributor.author | Wilkins, A | |
dc.contributor.author | Stuttle, C | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Hassan, S | |
dc.contributor.author | Pugh, J | |
dc.contributor.author | Cruickshank, C | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Corbishley, CM | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-09-11T12:30:57Z | |
dc.date.available | 2023-09-11T12:30:57Z | |
dc.date.issued | 2023-07-18 | |
dc.identifier.citation | BJU International, 2023, | |
dc.identifier.issn | 1464-4096 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5964 | |
dc.identifier.eissn | 1464-410X | |
dc.identifier.eissn | 1464-410X | |
dc.identifier.doi | 10.1111/bju.16133 | |
dc.description.abstract | OBJECTIVES: To compare the results of Gleason Grade Group (GGG) classification following central pathology review with previous local pathology assessment, and to examine the difference between using overall and worst GGG in a large patient cohort treated with radiotherapy and short-course hormone therapy. PATIENTS AND METHODS: Patients with low- to high-risk localized prostate cancer were randomized into the multicentre CHHiP fractionation trial between 2002 and 2011. Patients received short-course hormone therapy (≤6 month) and radical intensity-modulated radiotherapy (IMRT). Of 2749 consented patients, 1875 had adequate diagnostic biopsy tissue for blinded central pathology review. The median follow-up was 9.3 years. Agreement between local pathology and central pathology-derived GGG and between central pathology-derived overall and worst GGG was assessed using kappa (κ) statistics. Multivariate Cox regression and Kaplan-Meier methods were used to compare the biochemical/clinical failure (BCF) and distant metastases (DM) outcomes of patients with GGG 1-5. RESULTS: There was poor agreement between local pathology- and central pathology-derived GGG (κ = 0.19) but good agreement between overall and worst GGG on central pathology review (κ = 0.89). Central pathology-derived GGG stratified BCF and DM outcomes better than local pathology, while overall and worst GGG on central pathology review performed similarly. GGG 3 segregated with GGG 4 for BCF, with BCF-free rates of 90%, 82%, 74%, 71% and 58% for GGGs 1-5, respectively, at 8 years when assessed using overall GGG. There was a progressive decrease in DM-free rates from 98%, 96%, 92%, 88% and 83% for GGGs 1-5, respectively, at 8 years with overall GGG. Patients (n = 57) who were upgraded from GGG 2-3 using worst GS had BCF-free and DM-free rates of 74% and 92% at 8 years. CHHiP eligibility criteria limit the interpretation of these results. CONCLUSION: Contemporary review of International Society of Urological Pathology GGG successfully stratified patients treated with short-course hormone therapy and IMRT with regard to both BCF-free and DM-free outcomes. Patients upgraded from GGG 2 to GGG 3 using worst biopsy GS segregate with GGG 3 on long-term follow-up. We recommend that both overall and worst GS be used to derive GGG. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | BJU International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Gleason score | |
dc.subject | ISUP Grade Group | |
dc.subject | carcinoma | |
dc.subject | clinical trial | |
dc.subject | prostate | |
dc.subject | radiotherapy | |
dc.title | International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-07-18 | |
dc.date.updated | 2023-09-11T09:07:06Z | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1111/bju.16133 | |
rioxxterms.licenseref.startdate | 2023-07-18 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37463104 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/13/14 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1111/bju.16133 | |
icr.researchteam | Clinic Acad RT Dearnaley | |
icr.researchteam | Clin Trials & Stats Unit | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | Griffin, Clare | |
dc.contributor.icrauthor | Corbett, Anna | |
dc.contributor.icrauthor | Cruickshank, Clare | |
dc.contributor.icrauthor | Hall, Emma | |
icr.provenance | Deposited by Ms Sara Quirk (impersonating Mrs Clare Griffin) on 2023-09-11. Deposit type is initial. No. of files: 2. Files: ISUP Grade Groups in CHHiP Trial_REVISION_June2023_clean.docx; ISUP Grade Groups Supplementary Appendix_May2023_CLEAN.docx | |